Clinical trial
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy…
NCT00492544 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00492544 |
|---|---|
| Title | Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age |
| Official title | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 When Administered as a 3-dose Schedule in Healthy Japanese Pre-adolescent and Adolescent Female Subjects. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Cervarix™ (HPV-16/18 L1 VLP AS04) |
| Enrollment | 100 |
| Start date | Jul 2, 2007 |
| Primary completion | Mar 28, 2008 |
| Completion | Mar 28, 2008 |
| First posted | Jun 27, 2007 |
| Last update posted | Sep 4, 2018 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: